Actavis Totowa LLC, et al.; Withdrawal of Approval of Abbreviated New Drug Applications for Prescription Pain Medications Containing More Than 325 Milligrams of Acetaminophen; Correction, 24734 [2014-09898]
Download as PDF
<![CDATA[
24734
Federal Register / Vol. 79, No. 84 / Thursday, May 1, 2014 / Notices
receipt date will be the receipt date of
a complete User Fee Coversheet via
eSubmission. If a User Fee Coversheet is
submitted outside of normal business
hours (Monday to Friday, 8 a.m. to 4:30
p.m. excluding Federal holidays or
dates the Federal Government is
shutdown), the User Fee Coversheet
receipt date will be considered the next
business day.
4. Volunteers interested in
participating in the CDRH 510(k)
eSubmissions Pilot should contact
eSubmissions Pilot staff by email at
eSubpilot@fda.hhs.gov. This email
address should also be used to report
issues and ask questions. General
feedback and comments about the
eSubmissions Pilot, 510(k) template,
and process can be provided via
https://www.regulations.gov or the
Division of Dockets Management (see
Comments).
5. Additional information on the
CDRH 510(k) eSubmissions Pilot is
available at https://www.fda.gov/
ForIndustry/FDAeSubmitter/
ucm221506.htm.
III. Duration of the eSubmissions Pilot
FDA intends to accept requests for
participation in the eSubmissions Pilot
through September 30, 2014, or as
resources and eSubmissions Pilot needs
allow. Modifications to the CDRH 510(k)
eSubmissions Pilot will be made
available at https://www.fda.gov/
ForIndustry/FDAeSubmitter/
ucm221506.htm to all eSubmissions
Pilot participants and stakeholders.
eSubmissions Pilot for CDRH Electronic
Submission of Premarket Notification
Submissions to https://
www.regulations.gov or written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. It is only
necessary to send one set of comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: April 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–09912 Filed 4–30–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
FOR FURTHER INFORMATION CONTACT:
[Docket No. FDA–2011–N–0021]
Actavis Totowa LLC, et al.; Withdrawal
of Approval of Abbreviated New Drug
Applications for Prescription Pain
Medications Containing More Than 325
Milligrams of Acetaminophen;
Correction
Rachel Turow, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6236,
Silver Spring, MD 20993–0002, 301–
796–5094.
SUPPLEMENTARY INFORMATION:
Food and Drug Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
IV. Comments
Interested persons may submit
electronic comments regarding the
notice that appeared in the Federal
Register of March 27, 2014 (79 FR
17163). The document withdrew
approval of 108 abbreviated new drug
applications (ANDAs) for prescription
pain medications containing more than
325 milligrams (mg) of acetaminophen
per dosage unit from multiple
applicants, effective March 27, 2014.
The document failed to withdraw
approval of ANDAs 040825, 040822,
and 040824, held by Ranbaxy
Laboratories Inc. and Ranbaxy Inc., 600
College Rd. East, Princeton, NJ 08540,
and ANDA 040182, held by
Pharmaceutical Associates, Inc., 201
Delaware St., Greenville, SC 29605. The
holders of these applications have
voluntarily requested that approval of
these applications be withdrawn and
have waived their opportunity for a
hearing. FDA confirms the withdrawal
of approval of ANDAs 040825, 040824,
040822, and 040182.
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
SUMMARY:
In FR Doc.
2014–06801, appearing on page 17163,
in the Federal Register of Thursday,
March 27, 2014, the following
correction is made:
On page 17166, in table 1, the
following entries are added in
alphabetical order by Applicant:
Application
No.
Drug product(s)
Applicant or holder
ANDA 040182
Acetaminophen and Hydrocodone Bitartrate Oral Solution, 7.5
mg/500 mg/15 milliters (mL), available in 473 mL, 118 mL,
15 mL, and 10 mL.
Acetaminophen and Hydrocodone Bitartrate Tablets, 500 mg/5
mg.
Acetaminophen and Hydrocodone Bitartrate Tablets, 750 mg/
7.5 mg.
Acetaminophen and Hydrocodone Bitartrate Tablets, 500 mg/
10 mg.
Pharmaceutical Associates, Inc., 201 Delaware St., Greenville,
SC 29605.
ANDA 040825
ANDA 040822
ANDA 040824
Ranbaxy Laboratories Inc., 600 College Rd. East, Princeton,
NJ 08540.
Do.
Ranbaxy Inc., 600 College Rd. East, Princeton, NJ 08540.
tkelley on DSK3SPTVN1PROD with NOTICES
Dated: April 24, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–09898 Filed 4–30–14; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
17:30 Apr 30, 2014
Jkt 232001
PO 00000
Frm 00068
Fmt 4703
Sfmt 9990
E:\FR\FM\01MYN1.SGM
01MYN1
]]>Agencies
[Federal Register Volume 79, Number 84 (Thursday, May 1, 2014)]
[Notices]
[Page 24734]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-09898]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0021]
Actavis Totowa LLC, et al.; Withdrawal of Approval of Abbreviated
New Drug Applications for Prescription Pain Medications Containing More
Than 325 Milligrams of Acetaminophen; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register of March 27, 2014 (79 FR 17163).
The document withdrew approval of 108 abbreviated new drug applications
(ANDAs) for prescription pain medications containing more than 325
milligrams (mg) of acetaminophen per dosage unit from multiple
applicants, effective March 27, 2014. The document failed to withdraw
approval of ANDAs 040825, 040822, and 040824, held by Ranbaxy
Laboratories Inc. and Ranbaxy Inc., 600 College Rd. East, Princeton, NJ
08540, and ANDA 040182, held by Pharmaceutical Associates, Inc., 201
Delaware St., Greenville, SC 29605. The holders of these applications
have voluntarily requested that approval of these applications be
withdrawn and have waived their opportunity for a hearing. FDA confirms
the withdrawal of approval of ANDAs 040825, 040824, 040822, and 040182.
FOR FURTHER INFORMATION CONTACT: Rachel Turow, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6236, Silver Spring, MD 20993-0002, 301-
796-5094.
SUPPLEMENTARY INFORMATION: In FR Doc. 2014-06801, appearing on page
17163, in the Federal Register of Thursday, March 27, 2014, the
following correction is made:
On page 17166, in table 1, the following entries are added in
alphabetical order by Applicant:
------------------------------------------------------------------------
Application No. Drug product(s) Applicant or holder
------------------------------------------------------------------------
ANDA 040182......... Acetaminophen and Pharmaceutical
Hydrocodone Bitartrate Associates, Inc., 201
Oral Solution, 7.5 mg/ Delaware St.,
500 mg/15 milliters Greenville, SC 29605.
(mL), available in 473
mL, 118 mL, 15 mL, and
10 mL.
ANDA 040825......... Acetaminophen and Ranbaxy Laboratories
Hydrocodone Bitartrate Inc., 600 College Rd.
Tablets, 500 mg/5 mg. East, Princeton, NJ
08540.
ANDA 040822......... Acetaminophen and Do.
Hydrocodone Bitartrate
Tablets, 750 mg/7.5 mg.
ANDA 040824......... Acetaminophen and Ranbaxy Inc., 600
Hydrocodone Bitartrate College Rd. East,
Tablets, 500 mg/10 mg. Princeton, NJ 08540.
------------------------------------------------------------------------
Dated: April 24, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-09898 Filed 4-30-14; 8:45 am]
BILLING CODE 4160-01-P
